반응식
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:15]2[O:16][C:17]3[CH:23]=[CH:22][CH:21]=[CH:20][C:18]=3[N:19]=2)[CH:6]=[CH:7][C:8]=1[CH2:9][N:10]1C=[CH:13][N:12]=[N:11]1.Br[CH2:25][C:26]1[CH:31]=[CH:30][C:29]([C:32]2[O:33][C:34]3[CH:40]=[CH:39][CH:38]=[CH:37][C:35]=3[N:36]=2)=[CH:28][C:27]=1[O:41][CH3:42].[NH:43]1[CH:47]=[N:46][N:45]=[N:44]1>>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:15]2[O:16][C:17]3[CH:23]=[CH:22][CH:21]=[CH:20][C:18]=3[N:19]=2)[CH:6]=[CH:7][C:8]=1[CH2:9][N:10]1[N:11]=[N:12][CH:13]=[N:36]1.[CH3:42][O:41][C:27]1[CH:28]=[C:29]([C:32]2[O:33][C:34]3[CH:40]=[CH:39][CH:38]=[CH:37][C:35]=3[N:36]=2)[CH:30]=[CH:31][C:26]=1[CH2:25][N:43]1[CH:47]=[N:46][N:45]=[N:44]1참가 물질
반응물 3
생성물 2
실험 절차
Utilizing the general procedure outlined for 2-[3-methoxy-4-(1H-1,2,3-triazol-1-ylmethyl)phenyl]-1,3-benzoxazole, reaction of 2-[4-(bromomethyl)-3-methoxyphenyl]-1,3-benzoxazole (300 mg, 1.0 mmol) and 1H-tetrazole (70 mg, 1.0 mmol) afforded 2-[3-methoxy-4-(2H-tetrazol-2-ylmethyl)phenyl]-1,3-benzoxazole and 2-[3-methoxy-4-(1H-tetrazol-1-ylmethyl)phenyl]-1,3-benzoxazole as colorless solids. 2-[3-methoxy-4-(2H-tetrazol-2-ylmethyl)phenyl]-1,3-benzoxazole: 1H NMR (CDCl3, 300 MHz) δ 8.52 (s, 1H), 7.72–7.79 (m, 3H), 7.52–7.55 (m, 1H), 7.31–7.34 (m, 2H), 7.21 (d, 1H), 5.86 (s, 2H), 3.93 (s, 3H). MS (ESI) 308 (M+H). 2-[3-methoxy-4-(1H-tetrazol-1-ylmethyl)phenyl]-1,3-benzoxazole: 1H NMR (CDCl3, 300 MHz) δ 8.66 (s, 1H), 7.85 (d, 1H), 7.74–7.83 (m, 2), 7.55–7.59 (m, 1H), 7.41 (d, 1H), 7.34–7.40 (m, 2H), 5.61 (s, 2H), 3.98 (s, 3H). MS (ESI) 308 (M+H)+.
출처 및 근거
- ORD 기록
- ord-2b3841699031464c9e99c4979831a35d
- 출처 데이터셋
- uspto-grants-2006_08
- 특허 번호
- US07087601B2
연결된 노트
불러오는 중…